Literature DB >> 16877809

Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens.

Maria Constantinou1, Aleksandra Binka-Kowalska, Edyta Borkowska, Ewa Zajac, Paweł Jałmuzna, Józef Matych, Agnieszka Nawrocka, Bogdan Kałuzewski.   

Abstract

Multiplex FISH (UroVysion), Comparative Genomic Hybridization (CGH), and Multitemperature Single-Strand Conformation Polymorphism (MSSCP) were applied for non-invasive diagnosis and prognosis of bladder cancer. The UroVysion test was positive in 80% of patients with pT1 and in 100% of patients with either pT2 or pT3 tumours. Tumours with pT3T4 stages were characterized by high numbers of chromosomal imbalances, detected by CGH. The mutation of the p53 gene was detected in 16% of patients, but only in those with pT2 or pT3 tumours.

Entities:  

Mesh:

Year:  2006        PMID: 16877809     DOI: 10.1007/BF03194636

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  7 in total

1.  Molecular cytogenetic techniques in detecting subtle chromosomal imbalances.

Authors:  Bogdan Kałuzewski; Maria Constantinou; Ewa Zajac
Journal:  J Appl Genet       Date:  2003       Impact factor: 3.240

Review 2.  p53 and p53-regulated genes in bladder cancer.

Authors:  P E Keegan; J Lunec; D E Neal
Journal:  Br J Urol       Date:  1998-11

3.  Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine.

Authors:  S Ishiwata; S Takahashi; Y Homma; Y Tanaka; S Kameyama; Y Hosaka; T Kitamura
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

4.  Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.

Authors:  M G Friedrich; S Riethdorf; A Erbersdobler; C Tiemer; H Schwaibold; J K Sölter; E Huland; L Riethdorf; S Conrad; P G Hammerer; H Huland
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

5.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.

Authors:  I A Sokolova; K C Halling; R B Jenkins; H M Burkhardt; R G Meyer; S A Seelig; W King
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

6.  Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.

Authors:  Hans Boman; Hans Hedelin; Stefan Jacobsson; Sten Holmäng
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

7.  p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.

Authors:  H A Phillips; G C Howard; W R Miller
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  7 in total
  3 in total

1.  Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study.

Authors:  Nancy P Caraway; Abha Khanna; Ricardo L Fernandez; Linda Payne; Roland L Bassett; Hua-Zhong Zhang; Ashish Kamat; Ruth L Katz
Journal:  Cancer Cytopathol       Date:  2010-10-25       Impact factor: 5.284

2.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

3.  Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.

Authors:  Virginia López; Pilar González-Peramato; Javier Suela; Alvaro Serrano; Ferrán Algaba; Juan C Cigudosa; August Vidal; Joaquim Bellmunt; Oscar Heredero; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2013-08-01       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.